Business
BELLUS Health Announces Overnight Marketed Equity Offering
BELLUS Health Announces Overnight Marketed Equity Offering Canada NewsWire LAVAL...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health Announces Overnight Marketed Equity Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Dec. 4, 2017\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nLAVAL, QC, Dec. 4, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS Health\" or the \"Company\") today announced that it will undertake an overnight marketed offering of common shares. Bloom Burton Securities Inc. is acting as lead agent on behalf of a syndicate of agents that includes Cormark Securities Inc. and Mackie Research Capital Corporation. The offering is being made on a best efforts agency basis by the syndicate. The offering is to be effected in each of the Canadian provinces by way of a prospectus supplement to BELLUS Health's base shelf prospectus dated November 23, 2017. The common shares may also be offered for sale in the United States through one or more United States registered broker-dealer(s) appointed by the agents as sub-agent(s) pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the \"U.S. Securities Act\") and applicable state laws. Prior to the completion of the offering, BELLUS Health has 66,866,001 common shares issued and outstanding. The number of common shares to be distributed, the price of each common share and other terms of the offering will be determined in context of the market.\n\nThis transaction is subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.\n\nThe net proceeds of the offering will be used to fund research and development activities, including but not limited to, BLU-5937's clinical development, general and administrative expenses, working capital needs and other general corporate purposes.\n\nThe securities described herein have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and accordingly, may not be offered or sold...